Contate-nos
Sobre companhia
Equillium Inc is a biotechnology company that develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with an unmet medical need. Its primary product candidate is EQ001, which is a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.
US
Desconhecido
Empresa não verificada
Transparência de negócios
- Não verificou as informações da empresa
- Peça avaliações aos seus clientes
- Não respondeu a comentários negativos